Artificial Lymph Node (aLN) Matrix based T Cell-Stimulating Platform Development Service

aLN Overview

Lymph nodes are essential for the activation and coordination of T cell-mediated immune responses, where T cells engage with antigens and differentiate into effector cells to address infections. To tackle the challenges of T cell activation ex vivo in T cell therapies, researchers have developed a dynamic immune-stimulating scaffold known as an artificial lymph node (aLN). This innovative platform effectively replicates the roles of antigen-presenting cells and lymphatic tissue, facilitating direct in vivo stimulation of antigen-specific T cells. It recruits and organizes host immune cells, fostering an immuno-stimulatory environment that supports the in situ activation and proliferation of T cells specific to the target antigens, thus eliminating the necessity for ex vivo activation.

Fig.1 T cell activation and trafficking.¹

Key Features of aLN

aLN shows great potential in improving T cell therapy. Here are a few of aLN's salient characteristics:

Our Artificial Lymph Node (aLN) Matrix based T Cell-Stimulating Platform Development Service

Creative Biolabs offers a custom aLN-based artificial T cell-stimulating platform development service designed to accelerate cancer immunotherapy research. Our strategy harnesses cross-linking materials between different hydrogels to offer tailored T cell stimulation and activation in situ, incorporating user-specified T cell-stimulating signals. To enable effective platform development. We work directly with customers to customize the aLN, including hydrogels, ligands, costimulatory agents, and cytokines. At the same time, we continue to optimize the component concentrations and physical qualities for maximum T cell activation based on the testing results. Flexible, our service is suitable for a wide range of research purposes ranging from small and large-scale research initiatives.

As a one-stop service provider, we also provide comprehensive characterization services to identify platforms in phenotype and function. At Creative Biolabs, we are always committed to offering fast, high-quality solutions that help customers build more effective and long-lasting cancer T cell treatments.

Attractive Features

• Tailored platforms for precise T cell targeting and activation.
• Optimized natural lymphoid environment mimicry to promote physiological T cell activation, expansion, and differentiation.
• Optimized component concentrations to maximize T cell activation and proliferation.
• Thorough testing and analysis of the aLN matrix and the resulting T cell activation to ensure platform efficacy and reproducibility.
• Supports both small-scale and large-scale investigations, promoting translational research and development of cell therapies.
• End-to-end expert support, from design to analysis.

Associated Services

In addition to aLN, we also offer tailored solutions for various hydrogel-based materials, including aTM and immunomodulatory macroporous scaffolds, to develop advanced artificial T cell stimulation platforms that cater to our customers' unique requirements. Leveraging our profound knowledge in biomaterial engineering and T cell biology, we are adept at designing custom platforms that replicate particular lymphoid microenvironments, thereby improving the effectiveness and applicability of T cell-centric therapies.

• Artificial T Cell-Stimulating Matrix (aTM) based T Cell-Stimulating Platform Development Service
• Immunomodulatory Macroporous Scaffold based Artificial T Cell-Stimulating Platform Development Service

Creative Biolabs stands at the forefront of T cell therapy enhancement, combining deep theoretical insights with hands-on expertise in crafting innovative T cell stimulation platforms. Our specialization lies in the design and engineering of bespoke aLN-based solutions specifically aligned with your distinct research objectives. Reach out to us today to explore your specific requirements and discover how our expertise can help you create a highly effective aLN platform for the activation of T cells.

Reference

1. Notarbartolo, Samuele, and Sergio Abrignani. "Human T lymphocytes at tumor sites." Seminars in Immunopathology. Vol. 44. No. 6. Berlin/Heidelberg: Springer Berlin Heidelberg, 2022. Distributed under Open Access License CC BY 4.0, without modification.